Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Autopsy studies of latent prostate cancer provide important information for understanding the disease and, crucially, for addressing overdiagnosis. Further autopsy studies with standardized methods are needed to drive progress in this field, and studying the differences between latent and clinically significant prostate cancer might be a promising direction for future research.
Nearly 100 years since it was first used in humans as a vaccine for tuberculosis, Bacillus Calmette–Guérin (BCG) has been suggested as a possible agent to prevent coronavirus disease 2019 (COVID-19). A number of studies are underway to investigate this possibility but — even if they prove effective — many questions will remain.
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2, which invades a cell through binding to the ACE2 receptor and TMPRSS2 priming. Patients with severe disease predominantly present with pneumonia-related symptoms. However, evidence suggests that COVID-19 infection also has implications for the urogenital tract. Thus, urogenital organs should be considered when treating COVID-19.
Technology for the treatment of stone disease has rapidly advanced, but a common nomenclature to communicate research and high-quality studies to assess treatment outcomes are lacking. Thus, guidelines are based on low-grade evidence and cannot make definitive recommendations in many scenarios. To improve clinical practice and patient outcomes, the endourology community must unite to address these inadequacies.
The Urinary Tract Infection Global Alliance (UTIGA) — a new society in the field of urinary tract infection — has been established to promote cross-disciplinary interactions, provide access to new information, identify research needs and standardize patient management. UTIGA will also provide mentorship opportunities and patient advocacy.
Paediatric kidney tumours comprise many different subtypes, each being heterogeneous in their cellular as well as genetic composition. Advances in the past decade in 3D culture models create new opportunities for the generation of preclinical models capturing this phenotypic and genetic heterogeneity, potentially enabling the generation of patient-tailored therapies.
The world is currently in the grip of the COVID-19 pandemic. Rapid changes in medical priorities are being enforced across all health-care systems. Urologists have had to reduce or halt their clinical activity and assist on COVID-19 wards. The repercussions on urological patient outcomes for delayed treatments and diagnosis remain to be defined.